Head-To-Head Comparison: Kyntra Bio (NASDAQ:KYNB) and Pharmaxis (OTCMKTS:PXSLY)

Pharmaxis (OTCMKTS:PXSLY) and Kyntra Bio (NASDAQ:KYNB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Analyst Ratings

This is a summary of recent ratings and target prices for Pharmaxis and Kyntra Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharmaxis	0	0	0	0	0.00
Kyntra Bio	1	1	2	1	2.60

Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 339.78%. Given Kyntra Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than Pharmaxis.

Risk & Volatility

Pharmaxis has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

Institutional and Insider Ownership

72.7% of Kyntra Bio shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pharmaxis and Kyntra Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharmaxis	N/A	N/A	N/A
Kyntra Bio	2,199.13%	N/A	-36.71%

Valuation & Earnings

This table compares Pharmaxis and Kyntra Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharmaxis	$8.75 million	3.03	-$9.36 million	N/A	N/A
Kyntra Bio	$6.44 million	4.65	$183.45 million	$40.46	0.18

Kyntra Bio has lower revenue, but higher earnings than Pharmaxis.

Summary

Kyntra Bio beats Pharmaxis on 9 of the 12 factors compared between the two stocks.

About Pharmaxis

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.